Oliver Zill, data scientist, Guardant Health, discusses the somatic genomic landscape of over 15,000 patients with advanced-stage cancer from clinical next-generation sequencing analysis of circulating tumor DNA.

In the analysis, it was also found that the positive predictive value for finding actionable variance is high across key biomarkers, Zill explains. Researchers are also detecting actionable emerging resistance via circulating tumor DNA, which usually emerges after a patient undergoes a biopsy.

Oliver Zill

Articles

Next-Generation Sequencing Analysis of Circulating Tumor DNA